Your browser doesn't support javascript.
loading
Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms.
Zhang, Qi; Han, Qi; Zi, Jie; Ma, Jinlong; Song, Huihui; Tian, Yulu; McGrath, Mary; Song, Chunhua; Ge, Zheng.
Affiliation
  • Zhang Q; Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
  • Han Q; Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
  • Zi J; Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
  • Ma J; Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
  • Song H; Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
  • Tian Y; Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
  • McGrath M; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
  • Song C; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
  • Ge Z; Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
Genes Dis ; 6(3): 276-281, 2019 Sep.
Article in En | MEDLINE | ID: mdl-32042866
ABSTRACT
EZH2 is a component of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. EZH2 mutations are associated with oncogenesis and progression of cancers. However, the relationship between the clinical outcome of patients with myeloid malignancies and EZH2 mutations is controversial. Therefore, we performed a meta-analysis of 8 studies (n = 2243 patients) that evaluates the correlation between EZH2 mutations and overall survival (OS) in patients with myeloid neoplasms. EZH2 mutations were associated with significantly worse OS (hazard ratio [HR] = 2.37, 95% confidential interval (CI), 1.48-3.79). In a word, EZH2 mutations indicate a poor prognosis for patients with myeloid neoplasms.
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies / Systematic_reviews Language: En Journal: Genes Dis Year: 2019 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies / Systematic_reviews Language: En Journal: Genes Dis Year: 2019 Type: Article Affiliation country: China